165 related articles for article (PubMed ID: 25463039)
1. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties.
Karlsson JO; Ignarro LJ; Lundström I; Jynge P; Almén T
Drug Discov Today; 2015 Apr; 20(4):411-21. PubMed ID: 25463039
[TBL] [Abstract][Full Text] [Related]
2. Manganese- and Platinum-Driven Oxidative and Nitrosative Stress in Oxaliplatin-Associated CIPN with Special Reference to Ca
Karlsson JOG; Jynge P
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673932
[TBL] [Abstract][Full Text] [Related]
3. Mangafodipir as a cardioprotective adjunct to reperfusion therapy: a feasibility study in patients with ST-segment elevation myocardial infarction.
Karlsson JE; El-Saadi W; Ali M; Puskar W; Skogvard P; Engvall JE; Andersson RG; Maret E; Jynge P
Eur Heart J Cardiovasc Pharmacother; 2015 Jan; 1(1):39-45. PubMed ID: 27533964
[TBL] [Abstract][Full Text] [Related]
4. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: in vitro metabolism and protein binding studies of the active component MnDPDP in human blood.
Toft KG; Kindberg GM; Skotland T
J Pharm Biomed Anal; 1997 Apr; 15(7):983-8. PubMed ID: 9160265
[TBL] [Abstract][Full Text] [Related]
5. MnDPDP: Contrast Agent for Imaging and Protection of Viable Tissue.
Jynge P; Skjold AM; Falkmer U; Andersson RGG; Seland JG; Bruvold M; Blomlie V; Eidsaunet W; Karlsson JOG
Contrast Media Mol Imaging; 2020; 2020():3262835. PubMed ID: 32994754
[TBL] [Abstract][Full Text] [Related]
6. Cardioprotective effects of the MR contrast agent MnDPDP and its metabolite MnPLED upon reperfusion of the ischemic porcine myocardium.
Karlsson JO; Brurok H; Eriksen M; Towart R; Toft KG; Moen O; Engebretsen B; Jynge P; Refsum H
Acta Radiol; 2001 Nov; 42(6):540-7. PubMed ID: 11736698
[TBL] [Abstract][Full Text] [Related]
7. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties?
Brurok H; Ardenkjaer-Larsen JH; Hansson G; Skarra S; Berg K; Karlsson JO; Laursen I; Jynge P
Biochem Biophys Res Commun; 1999 Jan; 254(3):768-72. PubMed ID: 9920816
[TBL] [Abstract][Full Text] [Related]
8. Effects of MnDPDP, DPDP--, and MnCl2 on cardiac energy metabolism and manganese accumulation. An experimental study in the isolated perfused rat heart.
Brurok H; Schjøtt J; Berg K; Karlsson JO; Jynge P
Invest Radiol; 1997 Apr; 32(4):205-11. PubMed ID: 9101355
[TBL] [Abstract][Full Text] [Related]
9. Manganese-enhanced MRI of hypoxic-ischemic brain injuries using Mn-DPDP.
Yang J; Wu EX
Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():4775-8. PubMed ID: 19964849
[TBL] [Abstract][Full Text] [Related]
10. Mangafodipir trisodium injection, a new contrast medium for magnetic resonance imaging: detection and quantitation of the parent compound MnDPDP and metabolites in human plasma by high performance liquid chromatography.
Toft KG; Friisk GA; Skotland T
J Pharm Biomed Anal; 1997 Apr; 15(7):973-81. PubMed ID: 9160264
[TBL] [Abstract][Full Text] [Related]
11. Fodipir and its dephosphorylated derivative dipyridoxyl ethyldiamine are involved in mangafodipir-mediated cytoprotection against 7β-hydroxycholesterol-induced cell death.
Laskar A; Andersson RG; Li W
Pharmacology; 2013; 92(3-4):182-6. PubMed ID: 24080534
[TBL] [Abstract][Full Text] [Related]
12. Mangafodipir (MnDPDP)-and MnCl2-induced endothelium-dependent relaxation in bovine mesenteric arteries.
Asplund A; Grant D; Karlsson JO
J Pharmacol Exp Ther; 1994 Nov; 271(2):609-14. PubMed ID: 7965775
[TBL] [Abstract][Full Text] [Related]
13. Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR.
Schmidt PP; Toft KG; Skotland T; Andersson K
J Biol Inorg Chem; 2002 Mar; 7(3):241-8. PubMed ID: 11935348
[TBL] [Abstract][Full Text] [Related]
14. The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity.
Karlsson JO; Brurok H; Towart R; Jynge P
Cancer Res; 2006 Jan; 66(1):598; author reply 598. PubMed ID: 16397277
[No Abstract] [Full Text] [Related]
15. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs.
Toft KG; Hustvedt SO; Grant D; Friisk GA; Skotland T
Eur J Drug Metab Pharmacokinet; 1997; 22(1):65-72. PubMed ID: 9179562
[TBL] [Abstract][Full Text] [Related]
16. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
17. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
Wang C
Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
[TBL] [Abstract][Full Text] [Related]
18. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir.
Alexandre J; Nicco C; Chéreau C; Laurent A; Weill B; Goldwasser F; Batteux F
J Natl Cancer Inst; 2006 Feb; 98(4):236-44. PubMed ID: 16478742
[TBL] [Abstract][Full Text] [Related]
19. Plasma pharmacokinetics, tissue distribution and excretion of MnDPDP in the rat and dog after intravenous administration.
Hustvedt SO; Grant D; Southon TE; Zech K
Acta Radiol; 1997 Jul; 38(4 Pt 2):690-9. PubMed ID: 9245964
[TBL] [Abstract][Full Text] [Related]
20. Effects of manganese dipyridoxyl diphosphate, dipyridoxyl diphosphate--, and manganese chloride on cardiac function. An experimental study in the Langendorff perfused rat heart.
Brurok H; Schjøtt J; Berg K; Karlsson JO; Jynge P
Invest Radiol; 1995 Mar; 30(3):159-67. PubMed ID: 7797414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
